Objective: To investigate the expression and its clinical significance of Trop-2 in human pancreatic cancer.
Methods: Reverse transcription-polymerase chain reaction (RT-PCR) and immunofluorescence assay were used to characterize the expression of Trop-2 in human pancreatic cancer. The expression of Trop-2 protein in 31 tumor tissue samples, including peritumoral tissue from patients with pancreatic cancer, was detected with immunohistochemistry by tissue microarray. The clinicopathological characteristics and the tissue expression of Trop-2 protein were analyzed statistically.
Results: RT-PCR, immunofluorescence assay and immunohistochemistry by tissue microarray showed a high expression of Trop-2 in pancreatic cancer. The expression rate of Trop-2 was much higher in pancreatic cancer than that in peritumoral tissues (87.1% vs 9.7%). And a high expression of Trop-2 in pancreatic cancer was correlated with the low-differentiated changes. It had statistical significance (P < 0.05). In contrast, no statistically significant correlation was found between the expression of Trop-2 and gender or age.
Conclusion: The expression of Trop-2 is correlated with the development and malignancy of pancreatic cancer. As a clinical prognostic marker, Trop-2 may be a potential therapeutic target for pancreatic cancer.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Metformin-encapsulating immunoliposomes conjugated with anti-TROP 2 antibody fragments for the active targeting of triple-negative breast cancer.
Nanoscale
January 2025
UPR 4301 CBM, CNRS, NMNS Department, University of Tours, 37200 Tours, France.
Trophoblast cell-surface antigen 2 (TROP 2) has re-emerged as a promising biomarker in triple-negative breast cancer (TNBC), with high overexpression in many TNBC cases. However, despite its potential and approval as an antibody-drug-conjugate for TNBC treatment, TROP 2-targeted delivery systems are currently underexplored. Therefore, this study was aimed at exploiting the potential of TROP 2 targeting by encapsulating metformin (Met), an antidiabetic drug associated with tumor growth inhibitory properties, inside liposomes decorated with TROP 2-targeting single-chain variable fragments (scFvs).
View Article and Find Full Text PDFTrop-2 and Ephrin B2 expression in urothelial carcinoma with divergent differentiation and aggressive urothelial carcinoma subtypes.
Am J Clin Pathol
December 2024
Winship Cancer Institute of Emory University, Atlanta, GA, US.
Objectives: Urothelial carcinomas (UCs) encompass a heterogeneous group of tumors. Several histopathologic features are associated with poor clinical outcomes and limited treatment options. With new rising therapeutic modalities, we aimed to determine the pattern of expression of Trop-2 and ephrin B2 in UC with aggressive subtype histology and/or divergent differentiation (SH/DD).
View Article and Find Full Text PDFPredictive Factors of Antibody-Drug Conjugate Treatment in Metastatic Breast Cancer: A Narrative Review.
Cancers (Basel)
December 2024
Oncology Unit, "Dario Camberlingo" Hospital, 72021 Francavilla Fontana, Italy.
Antibody-drug conjugates (ADCs) have revolutionized the treatment landscape for metastatic breast cancer, offering targeted delivery of cytotoxic agents with improved efficacy and tolerability compared to conventional chemotherapy. This narrative review explores key predictive factors influencing the efficacy of ADCs, focusing on HER2-targeted therapies, such as trastuzumab emtansine and trastuzumab deruxtecan, as well as sacituzumab govitecan for triple-negative breast cancer. HER2 expression, TROP-2 levels, hormone receptor status, and the tumor microenvironment emerge as critical biomarkers for patient selection and therapeutic outcomes.
View Article and Find Full Text PDFSacituzumab Govitecan in Patients With Relapsed/Refractory Advanced Head and Neck Squamous Cell Carcinoma: Results From the Phase 2 TROPiCS-03 Basket Study.
Clin Cancer Res
December 2024
The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Purpose: Treatment options for advanced head and neck squamous cell carcinoma (HNSCC) previously treated with platinum-based chemotherapy and a programmed death-1 (PD-1) inhibitor are limited. Trophoblast cell-surface antigen 2 (Trop-2) is highly expressed in HNSCC. Sacituzumab govitecan (SG) is a Trop-2-directed antibody-drug conjugate approved for patients with certain previously treated solid tumors.
View Article and Find Full Text PDFA novel shark VNAR antibody-based immunotoxin targeting TROP-2 for cancer therapy.
Acta Pharm Sin B
November 2024
College of Marine Science and Biological Engineering, Qingdao University of Science and Technology, Qingdao 266042, China.
Article Synopsis
- - TROP-2, a protein linked to various types of cancer, is a potential target for new cancer treatments, specifically antibody-drug conjugates (ADCs), but their effectiveness against solid tumors is limited due to issues like poor penetration.
- - Researchers developed a small, stable immunotoxin using a shark-derived antibody known as VNAR, which has better tissue penetration properties than traditional antibodies.
- - The study identified a specific VNAR, called VNAR-5G8, which binds effectively to TROP-2 and created a recombinant immunotoxin (5G8-PE38) that showed strong anti-tumor activity, suggesting its potential as a cancer therapy option.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!